Vident Advisory LLC Reduces Position in Medpace Holdings, Inc. $MEDP

Key Points

• Vident Advisory LLC reduced its holdings in Medpace Holdings, Inc. by 17.9% during the first quarter, ending up with 3,871 shares valued at approximately $1.18 million.
• CEO August J. Troendle sold 36,196 shares of Medpace stock for over $17 million, decreasing his ownership by 3.76%.
• Medpace reported strong quarterly earnings, with $3.10 earnings per share, surpassing expectations of $3.00 and demonstrating a year-over-year revenue increase of 14.2%.

Vident Advisory LLC trimmed its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 17.9% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,871 shares of the company's stock after selling 845 shares during the period. Vident Advisory LLC's holdings in Medpace were worth $1,179,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Invesco Ltd. raised its position in shares of Medpace by 9.4% during the 1st quarter. Invesco Ltd. now owns 1,186,768 shares of the company's stock valued at $361,596,000 after purchasing an additional 102,015 shares during the period. Mawer Investment Management Ltd. bought a new stake in shares of Medpace during the 1st quarter valued at $212,131,000. Bessemer Group Inc. raised its position in shares of Medpace by 1.1% during the 1st quarter. Bessemer Group Inc. now owns 582,269 shares of the company's stock valued at $177,411,000 after purchasing an additional 6,225 shares during the period. Northern Trust Corp raised its position in shares of Medpace by 36.0% during the 1st quarter. Northern Trust Corp now owns 337,489 shares of the company's stock valued at $102,830,000 after purchasing an additional 89,347 shares during the period. Finally, Vulcan Value Partners LLC raised its position in shares of Medpace by 221.6% during the 1st quarter. Vulcan Value Partners LLC now owns 325,916 shares of the company's stock valued at $99,159,000 after purchasing an additional 224,578 shares during the period. 77.98% of the stock is currently owned by institutional investors.

Insider Activity

In related news, VP Susan E. Burwig sold 10,000 shares of Medpace stock in a transaction dated Wednesday, September 3rd. The shares were sold at an average price of $480.00, for a total transaction of $4,800,000.00. Following the completion of the sale, the vice president owned 57,500 shares in the company, valued at $27,600,000. This trade represents a 14.81% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO August J. Troendle sold 48,487 shares of Medpace stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $451.69, for a total transaction of $21,901,093.03. Following the sale, the chief executive officer owned 962,615 shares of the company's stock, valued at $434,803,569.35. The trade was a 4.80% decrease in their position. The disclosure for this sale can be found here. Insiders sold 161,266 shares of company stock worth $74,111,427 in the last 90 days. Company insiders own 20.30% of the company's stock.

Analyst Upgrades and Downgrades

MEDP has been the topic of a number of research reports. UBS Group downgraded shares of Medpace from a "neutral" rating to a "sell" rating and lifted their price target for the company from $300.00 to $305.00 in a report on Tuesday, July 29th. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Medpace from $270.00 to $430.00 and gave the company a "hold" rating in a report on Wednesday, July 23rd. Mizuho lifted their price target on shares of Medpace from $328.00 to $510.00 and gave the company an "outperform" rating in a report on Friday, July 25th. Robert W. Baird lifted their price target on shares of Medpace from $313.00 to $490.00 and gave the company a "neutral" rating in a report on Wednesday, July 23rd. Finally, Barclays lifted their price target on shares of Medpace from $300.00 to $450.00 and gave the company an "equal weight" rating in a report on Wednesday, July 23rd. Two research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and three have issued a Sell rating to the company's stock. According to MarketBeat.com, Medpace has a consensus rating of "Reduce" and an average target price of $412.73.

Medpace Stock Performance

Shares of NASDAQ:MEDP traded up $4.64 on Friday, reaching $486.98. The company's stock had a trading volume of 233,792 shares, compared to its average volume of 316,283. Medpace Holdings, Inc. has a 52-week low of $250.05 and a 52-week high of $501.30. The company has a market cap of $13.68 billion, a P/E ratio of 36.21, a PEG ratio of 3.06 and a beta of 1.44. The company has a 50-day simple moving average of $412.68 and a 200 day simple moving average of $344.19.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings data on Monday, July 21st. The company reported $3.10 EPS for the quarter, topping analysts' consensus estimates of $3.00 by $0.10. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The business had revenue of $603.31 million during the quarter, compared to analysts' expectations of $537.70 million. During the same period last year, the company posted $2.75 EPS. The business's revenue was up 14.2% on a year-over-year basis. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. On average, equities research analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.